We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries

By LabMedica International staff writers
Posted on 15 Mar 2024
Print article
Image: The new tuberculosis test could improve TB care globally (Photo courtesy of Shutterstock)
Image: The new tuberculosis test could improve TB care globally (Photo courtesy of Shutterstock)

Tuberculosis (TB) is one of the top infectious killers worldwide, second only to COVID-19. Keeping track of how well treatment works is key to fighting this disease. However, testing TB samples is tricky because it's highly infectious, requiring special high-security labs known as biosafety level 3 (BSL-3) labs. These labs have special equipment to keep the virus from spreading, but they're expensive and hard to find, especially in low- and middle-income countries where most TB cases are found. This makes fighting TB difficult in the places that need it most. Now, a new test allows testing for TB treatment monitoring to be done outside of a BSL-3 laboratory, potentially making it easier and faster to treat TB worldwide.

The new TB test — called rapid enumeration and diagnostic for tuberculosis (READ-TB) — was disclosed in the Association for Diagnostics & Laboratory Medicine's (ADLM, Washington, DC, USA) Clinical Chemistry journal and has been designed specifically to address the lack of access to labs that meet BSL-3 requirements. The test works by treating sputum (lung mucus coughed up by patients) with acetic acid. This acid kills the TB bacteria but leaves their RNA (genetic material) untouched. A lab worker can then safely check the RNA levels with a machine, which tells how much TB bacteria is in the patient and how well the treatment is working.

Acetic acid is better at preserving RNA than the current gold standard of using guanidium salts for two reasons: it kills the bacteria in just 30 minutes, thus eliminating the need for a BSL-3 lab, and it's just as effective at keeping the RNA safe. The RNA remains stable for 14 days at room temperature and for over a year if frozen at -20°C. This is ideal for labs without the capacity for super-cold storage. Plus, acetic acid is less toxic than guanidium salts, making it safer for lab workers. The READ-TB test isn't just safer and easier; it could also help with TB drug research. By accurately measuring TB RNA levels, scientists can compare different TB drugs or drug combinations more effectively.

"We wanted to improve the assay for integration into diagnostic microbiology laboratories, for use in clinical trials, and to make it tenable in low- and middle-income countries, e.g., where no BSL-3 laboratory exists," the authors of the study write, referring to their earlier test. "READ-TB allows measurement of the molecular bacterial load to now be adopted by routine clinical microbiology laboratories for measuring M. tuberculosis bacterial load in sputum."

Related Links:
ADLM

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.